argenx SE - American Depositary Shares (NQ:ARGX)

916.94 -2.27 (-0.25%)

Delayed Quote Updated: 1:45 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

argenx to Present at Upcoming Investor Conferences

November 07, 2022

From argenx SE

Via GlobeNewswire

McDonald's To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday ↗

October 28, 2022

Wedbush raised McDonald's Corporation (NYSE: MCD) price target from $265 to $300. Wedbush analyst Nick Setyan maintained the stock with an Outperform rating. McDonald's shares rose 3.3% to close at...

Via Benzinga

Recap: argenx Q3 Earnings ↗

October 27, 2022

argenx (NASDAQ:ARGX) reported its Q3 earnings results on Thursday, October 27, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings argenx missed estimated earnings by...

Via Benzinga

argenx Reports Third Quarter 2022 Financial Results and Provides Business Update

October 27, 2022

From argenx SE

Via GlobeNewswire

argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022

October 20, 2022

From argenx SE

Via GlobeNewswire

7 Analysts Have This to Say About argenx ↗

October 18, 2022

argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter:

Via Benzinga

Argenx's Drug Scores European Approval For Muscular Fatigue Disorder ↗

August 11, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022 ↗

October 12, 2022

Upgrades

Via Benzinga

Argenx's Vyvgart To 'Achieve Blockbuster Status,' This Analyst Says With 6% Price Target Hike ↗

July 29, 2022

Via Benzinga

argenx: Q2 Earnings Insights ↗

July 28, 2022

argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Recap: argenx Q2 Earnings ↗

July 28, 2022

argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say ↗

September 29, 2022

Via Benzinga

Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection ↗

September 21, 2022

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 11, 2022

Via Benzinga

Argenx Gets European Marketing Authorization For Neuromuscular Disorder Candidate ↗

August 11, 2022

The European Commission (EC) has granted marketing authorization for Argenx’s (NASDAQ: ARGX) lead asset VYVGART (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022 ↗

July 29, 2022

Via Benzinga

What 5 Analyst Ratings Have To Say About argenx ↗

July 25, 2022

Analysts have provided the following ratings for argenx (NASDAQ:ARGX) within the last quarter:

Via Benzinga

Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗

July 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022

July 28, 2022

From argenx SE

Via GlobeNewswire

argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update

July 28, 2022

From argenx SE

Via GlobeNewswire

Piper Sandler Maintains Overweight Rating for argenx: Here's What You Need To Know ↗

July 25, 2022

Piper Sandler has decided to maintain its Overweight rating of argenx (NASDAQ:ARGX) and raise its price target from $415.00 to $425.00. Shares of argenx are trading up 1.84% over the last 24 hours, at...

Via Benzinga

SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space ↗

May 24, 2022

Via Benzinga

Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study ↗

May 05, 2022

Via Benzinga

Recap: argenx Q1 Earnings ↗

May 05, 2022

argenx (NASDAQ:ARGX) reported its Q1 earnings results on Thursday, May 5, 2022 at 01:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Golden Cross Appears Before argenx Investors ↗

May 16, 2022

If history is any guide, there may be good fortune ahead for shares of argenx (NASDAQ:ARGX). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022 ↗

May 03, 2022

Upgrades

Via Benzinga

Argenx's Vyvgart Long-Term Treatment Shows Improved gMG Disease Scores ↗

April 05, 2022

Argenx SE (NASDAQ: ARGX) announced

Via Benzinga

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel ↗

April 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting

April 01, 2022

From argenx SE

Via Business Wire

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.